Welcome to LookChem.com Sign In|Join Free
  • or
(E)-3-(cyclopentyloxy)-N-(7-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methylhept-5-en-2-yl)benzenesulfonamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1380335-75-0

Post Buying Request

1380335-75-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1380335-75-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1380335-75-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,0,3,3 and 5 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1380335-75:
(9*1)+(8*3)+(7*8)+(6*0)+(5*3)+(4*3)+(3*5)+(2*7)+(1*5)=150
150 % 10 = 0
So 1380335-75-0 is a valid CAS Registry Number.

1380335-75-0Downstream Products

1380335-75-0Relevant academic research and scientific papers

Discovery of highly potent human deoxyuridine triphosphatase inhibitors based on the conformation restriction strategy

Miyahara, Seiji,Miyakoshi, Hitoshi,Yokogawa, Tatsushi,Chong, Khoon Tee,Taguchi, Junko,Muto, Toshiharu,Endoh, Kanji,Yano, Wakako,Wakasa, Takeshi,Ueno, Hiroyuki,Takao, Yayoi,Fujioka, Akio,Hashimoto, Akihiro,Itou, Kenjirou,Yamamura, Keisuke,Nomura, Makoto,Nagasawa, Hideko,Shuto, Satoshi,Fukuoka, Masayoshi

, p. 5483 - 5496 (2012/08/28)

Human deoxyuridine triphosphatase (dUTPase) inhibition is a promising approach to enhance the efficacy of thymidylate synthase (TS) inhibitor based chemotherapy. In this study, we describe the discovery of a novel class of human dUTPase inhibitors based on the conformation restriction strategy. On the basis of the X-ray cocrystal structure of dUTPase and its inhibitor compound 7, we designed and synthesized two conformation restricted analogues, i.e., compounds 8 and 9. These compounds exhibited increased in vitro potency compared with the parent compound 7. Further structure-activity relationship (SAR) studies identified a compound 43 with the highest in vitro potency (IC50 = 39 nM, EC50 = 66 nM). Furthermore, compound 43 had a favorable oral PK profile and exhibited potent antitumor activity in combination with 5-fluorouracil (5-FU) in the MX-1 breast cancer xenograft model. These results suggested that a dUTPase inhibitor may have potential for clinical usage.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1380335-75-0